ClinicalTrials.gg
CompletedNCT02436824Updated Aug 30, 2016

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

A Phase 2 interventional study of AB001 patch and Placebo patch in Chronic Low Back Pain, sponsored by Frontier Biotechnologies Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-08-30.

Sponsored by Frontier Biotechnologies Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
192nd of 623
146 · median 79
Started
2015
with 34 others
Phase 2
59 of 711
7 open now
Registered
315th of 711
by date

Among the 711 studies in Low Back Pain with a site in United States, this one is the 192nd largest by enrollment of the 623 interventional ones that give a count, is one of 35 that started in 2015, is one of 59 in phase 2, and was the 315th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 711 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to examine the safety, tolerability, and efficacy of repeated topical administration of AB001 topical patches for the treatment of chronic low back pain.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of AB001 topical patches in patients with chronic low back pain. Subjects meeting inclusion criteria are randomized in a 1:1 ratio to receive AB001 patches or placebo patches. Two AB001 or placebo patches will be given topically once daily for 14 days. The primary end point is the change of low back pain intensity rated on a visual analog scale (VAS) scale on Day 15, the secondary end points include the subject global assessment (SGA) of low back pain, the subject global perceived effect (GPE) of study medication, the Roland-Morris Disability Questionnaire (RMDQ), and the pain assessment from subject diary (Days 1 - 3 only). Subjects' safety will be monitored throughout the study, including the adverse event (AE) incidence and severity, laboratory test results (hematology and clinical chemistry), vital signs, and physical examination.

03

Conditions studied

  • Chronic Low Back Pain

Browse trials for

Keywords

  • topical patch
  • chronic low back pain
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are generally healthy males or non-pregnant females, 18 to 75 years of age.
  2. Have a (BMI) ≤35.
  3. Have chronic low back pain for at least 3 months.
  4. Have low back pain that is located inferior to the twelfth thoracic vertebra (T-12).
  5. Back pain classified, using the Quebec Task Force system, as either Class 1 or Class 2.
  6. Currently require use of analgesics for lower back pain (required at least 3 days per week for at least the last 4 weeks).
  7. Have a score of 30 mm or greater on the visual analog scale (VAS) and a score of 2, 3, or 4 on the Subject Global Assessment (SGA) of Back Pain Scale at Screening.
  8. Are willing to discontinue current analgesics for the 3 to 15 day .
  9. Have an increase of at least 10 mm or more from the score at Screening and an absolute score of 50 mm or more on the VAS (ie, VAS ≥ 50 mm) and a score of 3 or 4 on the SGA of Back Pain Scale at Baseline.
  10. If female, are: 1).Of non- or have a confirmed clinical history of sterility or, 2).Of childbearing potential, must be willing to use effective at trial entry and until completion.
  11. Are willing to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Have chronic lower back pain (CLBP) due to any of the following pathologies: infection, neoplasia, metabolic or structural disturbance of spine, lumbar radiculopathy, osteoporosis, hip dysplasia, inflammatory arthritis, ankylosing spondylitis, Paget's disease, cauda equine syndrome, gout, pseuodgout, fibromyalgia, post-surgical pain.
  2. Have low back pain caused by major trauma.
  3. Have excess hair, tattoo(s), or other dermatologic conditions in the patch application area that might interfere with efficacy evaluation.
  4. Have had surgery for low back pain within the previous 6 months.
  5. Have had clinical depression within 2 years or are currently undergoing treatment for depression;
  6. Have a to non-steroidal anti-inflammatory drugs (NSAIDs, including aspirin) or hypersensitivity to acetaminophen.
  7. Have used opioids within 72 hours prior to the Baseline / Day 1 visit or during the course of the study.
  8. Have used oral or injected chronically or intermittently within the past 60 days (oral), or 90 days (injected).
  9. Are a current drug or alcohol abuser.
  10. Are pregnant, plan to become pregnant during the study, or are breastfeeding.
  11. Have a pending workman's compensation claim, litigation, or any other monetary settlement relating to the subject's lower back pain.
  12. Have any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial.
  13. Have a history of sensitivity to any component of the product.
  14. Have a known history of liver or kidney disorders (hepatic or renal insufficiency).
  15. Have a known history of gastric ulcer, gastrointestinal bleeding, or significant cardiovascular events.
  16. Have a history of cancer, other than treated basal cell carcinoma, within the past 5 years.
  17. Use of any medication, including prescription, OTC, vitamins, herbal and/or mineral supplements, dietary supplements, enzyme altering agents within at least14 days prior to the first treatment or during the trial, which may influence the trial results.
  18. Use of anti-coagulant medication within the past 30 days, including but not limited to heparins, warfarin/Coumadin, rivaroxaban/Xarelto, dabigatran/Pradaxa, apixaban/Eliquis, etc.
  19. Participation in another clinical trial or received an investigational product within 30 days prior to screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    AB001 patch

    Two AB001 patches will be applied to the low back once daily for 14 days.

    Drug: AB001 patch

  • Placebo comparator
    Placebo patch

    Identical in size and shape to the AB001 patch. Two placebo patches will be applied to the low back once daily for 14 days.

    Other: Placebo patch

Interventions

  • Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.

    Also known as: AB001

  • OtherPlacebo patch

    Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.

06

What researchers measure

Primary outcomes

  1. Change of Pain intensity on VAS on Day 15

    Time frame: From baseline to Day 15

Secondary outcomes

  1. Change of Pain intensity on VAS on Day 8

    Time frame: From baseline to Day 8

  2. Change of Subject Global Assessment (SGA) of disease status/low back pain

    Time frame: From baseline to Day 8 and 15

  3. Change of Roland-Morris Disability Questionnaire on low back pain

    Time frame: From baseline to Day 8 and 15

  4. Subject Global Perceived Effect (GPE) of study medication

    Time frame: From baseline to Day 8 and 15

  5. Pain Assessment from Subject Diaries

    Time frame: On Day 1 through Day 3

  6. Safety Assessments on AEs

    Time frame: From baseline through Day 15

  7. Safety Assessments on laboratory test

    Time frame: From baseline through Day 15

  8. Safety Assessments on vital signs/physical examinations

    Time frame: From baseline through Day 15

07

Study locations

9 sites
  • San Marcus Research Clinic, Inc.
    Miami, Florida 33015, United States
  • Pharma Research International, Inc.
    Naples, Florida 34102, United States
  • Georgia Institute for Clinical Research,LLC
    Marietta, Georgia 30060, United States
  • Central Kentucky Research Associates
    Lexington, Kentucky 40509, United States
  • Atco Medical Associates, P.C.
    Atco, New Jersey 08004, United States
  • UniMed Center
    East Brunswick, New Jersey 08816, United States
  • TKL Research, Inc.
    Fair Lawn, New Jersey 07410, United States
  • Upstate Clinical Trials, LLC
    Spartanburg, South Carolina 29307, United States
  • Danville Orthopedic Clinic, Inc.
    Danville, Virginia 24541, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Jul 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2015
First posted
May 7, 2015
Start
Apr 2015
Primary completionActual
Jul 2015
CompletionActual
Aug 2015
Results delay requested
Aug 25, 2016
Last update
Aug 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02436824
Lead sponsor
Frontier Biotechnologies Inc.
Responsible party
Sponsor
First posted
May 7, 2015
Start date
Apr 2015
Primary completion
Jul 2015
Completion
Aug 2015
Last update
Aug 30, 2016

Study contacts

Changjin Wang
study director · Frontier Biotechnologies Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AB-001

Start the discussion